Nina Niu Sanford, Assistant Professor and Chief of Gastrointestinal Radiation Oncology at Harvard/Brigham and Women’s Hospital/Massachusetts General Hospital, shared a post on X:
“Important survivorship data for anal SCC. Definitive chemoRT achieves cure in most, but with substantial functional cost. In PRO study, 62% of pts w/o stoma had major LARS.
De-escalation RCTs (DECREASE fully accrued, PLATO-ACT4 w early results) critical for improving QOL.”
Title: Patient-reported quality of life after chemoradiotherapy in patients with non-metastatic anal squamous cell carcinoma: A cross-sectional cohort study
Authors: Rianne A. Lunenberg, Felice N. van Erning, Floris P. C. Sijtsma, Ignace H. J. T. de Hingh, Bregje van Triest, Bas A. Grotenhuis, Mees Koopman, Marc P. W. Intven, Jorine M. L. Roodhart, Johannes J. M. Kwakman.
Read the article here.
Other articles about Quality of Life on OncoDaily.
